Steinberg G H, Kandel M, Kandel S I, Wells J W
Biochemistry. 1985 Oct 22;24(22):6115-25. doi: 10.1021/bi00343a013.
The binding of [3H]histamine to H2 receptors in homogenates of rat cerebral cortex is inhibited by 11 H2 agonists in a characteristic and unique manner. At low concentrations of the radioligand (less than 1.5 nM), the inhibitory profiles of individual agonists (A) are distinctly biphasic; specific binding is well described in most cases by the empirical expression Y = F1K1/(K1 + [A]) + F2K2/(K2 + [A]), in which F1 and F2 sum to 1. Maximal inhibition is the same for all agonists. Since values of F2 vary from 0.42 to 0.90, the agonist appears to determine the equilibrium distribution of receptors between two states of affinity. Ratios of apparent affinity (K2/K1) vary from 204 to 3 090 000, and there is no correlation between values of K1 and K2. Compounds lacking H2 activity, including structural analogues of histamine and dimaprit, reveal a Hill coefficient of 1 and inhibit the radioligand only weakly. For six agonists, values of K2 agree and correlate well (P = 0.00047) with H2 pharmacological potency (EC50) in the guinea pig right atrium; for the others, K2 is less than EC50 by 15-61-fold. Four observations suggest that the inhibition corresponding to F1 is allosteric and cooperative: the dissociation constant of the radioligand appears to vary in the presence of an unlabeled agonist, absolute levels of binding corresponding to F1, as defined by dimaprit, decrease at higher concentrations of [3H]histamine, F1 for dimaprit is reduced from 0.48 to 0.32 by 2-methylhistamine (F1 = 0.27) at a concentration of 20 nM (approximately K1(0.5) K2(0.5) for 2-methylhistamine), but the increase in K1 for dimprit is at least 100-fold less than expected from competitive effects, and 1 equiv of some agonists appears to preclude access of [3H]histamine to more than 1 equiv of receptors, with no evidence that an appreciable fraction of the unlabeled drug is bound. Noncompetitive effects also may account in part for the inhibition corresponding to F2.
[3H]组胺与大鼠大脑皮层匀浆中H2受体的结合受到11种H2激动剂的抑制,且抑制方式具有独特的特征。在低浓度放射性配体(低于1.5 nM)时,各激动剂(A)的抑制曲线明显呈双相;在大多数情况下,特异性结合可用经验表达式Y = F1K1/(K1 + [A]) + F2K2/(K2 + [A])很好地描述,其中F1和F2之和为1。所有激动剂的最大抑制程度相同。由于F2值在0.42至0.90之间变化,激动剂似乎决定了受体在两种亲和力状态之间的平衡分布。表观亲和力比值(K2/K1)在204至3090000之间变化,且K1和K2值之间无相关性。缺乏H2活性的化合物,包括组胺的结构类似物和二甲双胍,其希尔系数为1,对放射性配体的抑制作用较弱。对于六种激动剂,K2值与豚鼠右心房中的H2药理活性(EC50)一致且相关性良好(P = 0.00047);对于其他激动剂,K2比EC50低15至61倍。有四项观察结果表明,对应于F1的抑制是变构性且具有协同性:在未标记激动剂存在下,放射性配体的解离常数似乎会发生变化,由二甲双胍定义的对应于F1的结合绝对水平在较高浓度的[3H]组胺时会降低,在20 nM(约为2 - 甲基组胺的K1(0.5) K2(0.5))浓度下,2 - 甲基组胺使二甲双胍的F1从0.48降至0.32(F1 = 0.27),但二甲双胍K1的增加至少比竞争效应预期的小100倍,并且1当量的某些激动剂似乎会阻止[3H]组胺与超过1当量的受体结合,没有证据表明有相当一部分未标记药物被结合。非竞争性效应也可能部分解释了对应于F2的抑制作用。